# Delandistrogene moxeparvovec with the requested indication PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/delandistrogene-moxeparvovec-with-the-requested-indication

> Delandistrogene moxeparvovec with the requested indication, sponsored by Sarepta Therapeutics, Inc. (SRPT): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | delandistrogene moxeparvovec with the requested indication |
| Codes |  |
| Sponsor | Sarepta Therapeutics, Inc. (SRPT) https://sec-api.dev/companies/srpt/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### May 12, 2023: FDA advisory committee meeting

- Status: completed. Date confidence: exact.
- First seen 2026-11-12T16:13:16.857Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "On May 12, 2023, the committee will meet in open session to discuss the Biologics License Application (BLA) 125781 from Sarepta Therapeutics, Inc. for delandistrogene moxeparvovec with the requested indication for the treatment of ambulatory patients with Duchenne Muscular Dystrophy (DMD) with a confirmed mutation in the DMD gene." https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-may-12-2023-meeting-announcement-05122023

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/delandistrogene-moxeparvovec-with-the-requested-indication.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Delandistrogene moxeparvovec with the requested indication PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/delandistrogene-moxeparvovec-with-the-requested-indication

```bibtex
@misc{secapidev_pdufa_delandistrogene_moxeparvovec_with_the_requested_indication_20261116,
  title        = {Delandistrogene moxeparvovec with the requested indication PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/delandistrogene-moxeparvovec-with-the-requested-indication}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_delandistrogene_moxeparvovec_with_the_requested_indication_20261116","title":"Delandistrogene moxeparvovec with the requested indication PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/delandistrogene-moxeparvovec-with-the-requested-indication","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
